US2022275419A1PendingUtilityA1

Method for the preparation of low molecular weight porcine lympho-reticular polypeptides and formulations thereof

Assignee: DE URBINA SANTIAGOPriority: Aug 15, 2019Filed: Aug 15, 2020Published: Sep 1, 2022
Est. expiryAug 15, 2039(~13 yrs left)· nominal 20-yr term from priority
C12Y 304/22002C12N 9/50C12P 21/06C12Y 301/03008C07K 14/47C12Y 302/01001C12Y 304/23001
38
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A method for preparation of low molecular weight porcine lympho-reticular polypeptides. The method comprises the enzymatic hydrolysis of a source of protein, wherein the source of protein comprises a blend of porcine liver and porcine spleen, with a first enzyme having proteolytic activity and a second enzyme having amylase activity.

Claims

exact text as granted — not AI-modified
1 . (canceled) 
     
     
         2 . (canceled) 
     
     
         3 . (canceled) 
     
     
         4 . (canceled) 
     
     
         5 . (canceled) 
     
     
         6 . (canceled) 
     
     
         7 . (canceled) 
     
     
         8 . (canceled) 
     
     
         9 . (canceled) 
     
     
         10 . (canceled) 
     
     
         11 . (canceled) 
     
     
         12 . (canceled) 
     
     
         13 . (canceled) 
     
     
         14 . (canceled) 
     
     
         15 . (canceled) 
     
     
         16 . (canceled) 
     
     
         17 . A low molecular weight porcine lympho-reticular polypeptides formulation, comprising:
 a low molecular weight porcine lympho-reticular polypeptide, a vitamin, an antioxidant, and zinc.   
     
     
         18 . The low molecular weight porcine lympho-reticular polypeptides formulation of  claim 17 , wherein the antioxidant is alpha lipoic acid. 
     
     
         19 . The low molecular weight porcine lympho-reticular polypeptides formulation of  claim 17 , wherein the antioxidant is selected from resveratrol, glutathione, quercetin or astaxanthin, or combinations thereof. 
     
     
         20 . The low molecular weight porcine lympho-reticular polypeptides formulation of  claim 17 , wherein the zinc is zinc gluconate dihydrate or zinc glycinate chelate. 
     
     
         21 . The low molecular weight porcine lympho-reticular polypeptides formulation of  claim 17 , wherein the vitamin is selected from vitamin C, vitamin D3, vitamin B1, vitamin B2, vitamin B3, vitamin B5, vitamin B6, vitamin B12, biotin, and folic acid, or combinations thereof. 
     
     
         22 . A low molecular weight porcine lympho-reticular polypeptides formulation, comprising:
 low molecular weight porcine lympho-reticular polypeptide, a vitamin, bovine thymus extract, ascorbic acid, resveratrol, and zinc.   
     
     
         23 . The low molecular weight porcine lympho-reticular polypeptides formulation of  claim 22 , wherein the vitamin is selected from vitamin C, vitamin D3, vitamin B1, vitamin B2, vitamin B3, vitamin B5, vitamin B6, vitamin B12, biotin, and folic acid, or combinations thereof. 
     
     
         24 . The low molecular weight porcine lympho-reticular polypeptides formulation of  claim 22 , wherein the zinc is zinc gluconate dihydrate or zinc glycinate chelate. 
     
     
         25 . A low molecular weight porcine lympho-reticular polypeptides formulation, comprising:
 a low molecular weight porcine lympho-reticular polypeptide, an antioxidant, alpha glycerylphophorylcholine, and zinc.   
     
     
         26 . The low molecular weight porcine lympho-reticular polypeptides formulation of  claim 25 , wherein the antioxidant is alpha lipoic acid. 
     
     
         27 . The low molecular weight porcine lympho-reticular polypeptides formulation of  claim 25 , wherein the antioxidant is selected from resveratrol, glutathione, quercetin or astaxanthin, or combinations thereof. 
     
     
         28 . The low molecular weight porcine lympho-reticular polypeptides formulation of  claim 25 , wherein the zinc is zinc gluconate dihydrate or zinc glycinate chelate. 
     
     
         29 . A low molecular weight porcine lympho-reticular polypeptides formulation, comprising:
 a low molecular weight porcine lympho-reticular polypeptide, a vitamin, ascorbic acid, and zinc.   
     
     
         30 . The low molecular weight porcine lympho-reticular polypeptides formulation of  claim 29 , wherein the zinc is zinc gluconate dihydrate or zinc glycinate chelate. 
     
     
         31 . The low molecular weight porcine lympho-reticular polypeptides formulation of  claim 30 , wherein the vitamin is selected from vitamin C, vitamin D3, vitamin B1, vitamin B2, vitamin B3, vitamin B5, vitamin B6, vitamin B12, biotin, and folic acid, or combinations thereof. 
     
     
         32 . A low molecular weight porcine lympho-reticular polypeptides formulation, comprising:
 a low molecular weight porcine lympho-reticular polypeptide, chondroitin, an antioxidant, and glucosamine.   
     
     
         33 . The low molecular weight porcine lympho-reticular polypeptides formulation of  claim 32 , wherein the antioxidant is alpha lipoic acid. 
     
     
         34 . The low molecular weight porcine lympho-reticular polypeptides formulation of  claim 32 , wherein the antioxidant is selected from resveratrol, glutathione, quercetin or astaxanthin, or combinations thereof. 
     
     
         35 . A low molecular weight porcine lympho-reticular polypeptides formulation, comprising:
 a low molecular weight porcine lympho-reticular polypeptide, an antioxidant, L-Carnitine, a vitamin, and magnesium chloride.   
     
     
         36 . The low molecular weight porcine lympho-reticular polypeptides formulation of  claim 35 , wherein the antioxidant is alpha lipoic acid. 
     
     
         37 . The low molecular weight porcine lympho-reticular polypeptides formulation of  claim 35 , wherein the antioxidant is selected from resveratrol, glutathione, quercetin or astaxanthin, or combinations thereof. 
     
     
         38 . The low molecular weight porcine lympho-reticular polypeptides formulation of  claim 35 , wherein the vitamin is selected from vitamin C, vitamin D3, vitamin B1, vitamin B2, vitamin B3, vitamin B5, vitamin B6, vitamin B12, biotin and folic acid, or combinations thereof. 
     
     
         39 . (canceled) 
     
     
         40 . The low molecular weight porcine lympho-reticular polypeptides formulation of any of  claim 32 , wherein the amino acid is L-Lysine.

Join the waitlist — get patent alerts

Track US2022275419A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.